These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 7931201)

  • 41. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome.
    Vercoulen JH; Swanink CM; Zitman FG; Vreden SG; Hoofs MP; Fennis JF; Galama JM; van der Meer JW; Bleijenberg G
    Lancet; 1996 Mar; 347(9005):858-61. PubMed ID: 8622391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A controlled comparison of fluoxetine and amitriptyline in depressed out-patients.
    Young JP; Coleman A; Lader MH
    Br J Psychiatry; 1987 Sep; 151():337-40. PubMed ID: 3322468
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A meta-analysis of antidepressant outcome under "blinder" conditions.
    Greenberg RP; Bornstein RF; Greenberg MD; Fisher S
    J Consult Clin Psychol; 1992 Oct; 60(5):664-9; discussion 670-7. PubMed ID: 1401382
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression.
    Beasley CM; Bosomworth JC; Wernicke JF
    Psychopharmacol Bull; 1990; 26(1):18-24. PubMed ID: 2196623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of fluoxetine on dexamethasone-induced growth hormone release in depression: a double-blind, placebo-controlled study.
    Thakore JH; Dinan TG
    Am J Psychiatry; 1995 Apr; 152(4):616-8. PubMed ID: 7694914
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical pharmacokinetics of fluoxetine.
    Altamura AC; Moro AR; Percudani M
    Clin Pharmacokinet; 1994 Mar; 26(3):201-14. PubMed ID: 8194283
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Magnitude of placebo response in clinical trials of paroxetine for vasomotor symptoms: a meta-analysis.
    Rhodes JR; Alldredge CT; Elkins GR
    Front Psychiatry; 2023; 14():1204163. PubMed ID: 37599891
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PROTOCOL: Treatment for depressive disorder among adults: An evidence and gap map of systematic reviews.
    Guo L; Li J; White H; Xu Z; Ren J; Huang X; Chen Y; Yang K
    Campbell Syst Rev; 2023 Mar; 19(1):e1308. PubMed ID: 36911856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of active placebo controls on estimated drug effects in randomised trials: a systematic review of trials with both active placebo and standard placebo.
    Laursen DR; Nejstgaard CH; Bjørkedal E; Frost AD; Hansen MR; Paludan-Müller AS; Prosenz J; Werner CP; Hróbjartsson A
    Cochrane Database Syst Rev; 2023 Mar; 3(3):MR000055. PubMed ID: 36877132
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Socially transmitted placebo effects.
    Chen PA; Cheong JH; Jolly E; Elhence H; Wager TD; Chang LJ
    Nat Hum Behav; 2019 Dec; 3(12):1295-1305. PubMed ID: 31636406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Placebo Effect in the Treatment of Depression and Anxiety.
    Kirsch I
    Front Psychiatry; 2019; 10():407. PubMed ID: 31249537
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is the efficacy of antidepressants in panic disorder mediated by adverse events? A mediational analysis.
    Bighelli I; Borghesani A; Barbui C
    PLoS One; 2017; 12(6):e0178617. PubMed ID: 28575031
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is the Efficacy of Antidepressants Truly a Myth?
    Linde K; Sigterman K
    Glob Adv Health Med; 2012 Nov; 1(5):12-3. PubMed ID: 27257522
    [No Abstract]   [Full Text] [Related]  

  • 54. Lessons learned from placebo groups in antidepressant trials.
    Mora MS; Nestoriuc Y; Rief W
    Philos Trans R Soc Lond B Biol Sci; 2011 Jun; 366(1572):1879-88. PubMed ID: 21576145
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Personality change during depression treatment: a placebo-controlled trial.
    Tang TZ; DeRubeis RJ; Hollon SD; Amsterdam J; Shelton R; Schalet B
    Arch Gen Psychiatry; 2009 Dec; 66(12):1322-30. PubMed ID: 19996037
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
    Shih YC; Bekele NB; Xu Y
    Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blindness and bias in a trial of antidepressant medication for chronic tension-type headache.
    Holroyd KA; Tkachuk G; O'Donnell F; Cordingley GE
    Cephalalgia; 2006 Aug; 26(8):973-82. PubMed ID: 16886934
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons.
    Eckert L; Lançon C
    BMC Psychiatry; 2006 Jul; 6():30. PubMed ID: 16867188
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Active placebos versus antidepressants for depression.
    Moncrieff J; Wessely S; Hardy R
    Cochrane Database Syst Rev; 2004; 2004(1):CD003012. PubMed ID: 14974002
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fluoxetine: a review on evidence based medicine.
    Rossi A; Barraco A; Donda P
    Ann Gen Hosp Psychiatry; 2004 Feb; 3(1):2. PubMed ID: 14962351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.